JP2024506116A5 - - Google Patents

Info

Publication number
JP2024506116A5
JP2024506116A5 JP2023531615A JP2023531615A JP2024506116A5 JP 2024506116 A5 JP2024506116 A5 JP 2024506116A5 JP 2023531615 A JP2023531615 A JP 2023531615A JP 2023531615 A JP2023531615 A JP 2023531615A JP 2024506116 A5 JP2024506116 A5 JP 2024506116A5
Authority
JP
Japan
Prior art keywords
optionally substituted
pharmaceutically acceptable
acceptable salt
cancer
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023531615A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506116A (ja
JP7895947B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/133429 external-priority patent/WO2022111621A1/en
Publication of JP2024506116A publication Critical patent/JP2024506116A/ja
Publication of JP2024506116A5 publication Critical patent/JP2024506116A5/ja
Application granted granted Critical
Publication of JP7895947B2 publication Critical patent/JP7895947B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023531615A 2020-11-27 2021-11-26 アミノヘテロアリールキナーゼ阻害剤 Active JP7895947B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/132454 2020-11-27
CN2020132454 2020-11-27
CNPCT/CN2021/081236 2021-03-17
CN2021081236 2021-03-17
PCT/CN2021/133429 WO2022111621A1 (en) 2020-11-27 2021-11-26 Aminoheteroaryl kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2024506116A JP2024506116A (ja) 2024-02-09
JP2024506116A5 true JP2024506116A5 (cg-RX-API-DMAC7.html) 2024-12-04
JP7895947B2 JP7895947B2 (ja) 2026-07-28

Family

ID=81753779

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023531615A Active JP7895947B2 (ja) 2020-11-27 2021-11-26 アミノヘテロアリールキナーゼ阻害剤
JP2024531423A Pending JP2024541533A (ja) 2020-11-27 2022-11-23 アミノヘテロアリールキナーゼ阻害薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024531423A Pending JP2024541533A (ja) 2020-11-27 2022-11-23 アミノヘテロアリールキナーゼ阻害薬

Country Status (10)

Country Link
US (2) US20240166635A1 (cg-RX-API-DMAC7.html)
EP (2) EP4251613A4 (cg-RX-API-DMAC7.html)
JP (2) JP7895947B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230127228A (cg-RX-API-DMAC7.html)
CN (3) CN122483000A (cg-RX-API-DMAC7.html)
AU (3) AU2021385745C1 (cg-RX-API-DMAC7.html)
CA (2) CA3202990A1 (cg-RX-API-DMAC7.html)
IL (1) IL303237A (cg-RX-API-DMAC7.html)
MX (1) MX2024006300A (cg-RX-API-DMAC7.html)
WO (2) WO2022111621A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4251613A4 (en) * 2020-11-27 2024-11-20 Allorion Therapeutics Inc. AMINOHETEROARYL KINASE INHIBITORS
US20250009745A1 (en) * 2021-02-05 2025-01-09 Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. Cdk inhibitor
CN119343333A (zh) * 2022-05-27 2025-01-21 安锐生物医药公司 氨基杂芳基激酶抑制剂
WO2025006400A1 (en) * 2023-06-25 2025-01-02 Allorion Therapeutics Inc Isotopologues of aminoheteroaryl kinase inhibitors and uses thereof
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers
EP4725942A1 (en) * 2024-10-09 2026-04-15 Sibylla Biotech S.p.A. Compounds active on cyclin d1 pathway and their use

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0021726D0 (en) * 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
MXPA03005696A (es) * 2000-12-21 2003-10-06 Glaxo Group Ltd Pirimidinaminas como moduladores de angiogenesis.
IL159120A0 (en) * 2001-05-29 2004-05-12 Schering Ag Cdk inhibiting pyrimidines, production thereof and their use as medicaments
GB0113041D0 (en) * 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
HUP0402245A3 (en) * 2001-11-01 2010-03-29 Janssen Pharmaceutica Nv Pyrimidinyl-aminobenzamide derivatives as glycogen synthase kinase 3betha inhibitors, their use, pharmaceutical compositions containing them and process for producing them
GB0205693D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205688D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
JP2005526765A (ja) 2002-03-11 2005-09-08 シエーリング アクチエンゲゼルシャフト Cdk−阻害性2−ヘテロアリール−ピリミジン類、それらの生成及び医薬としての使用
WO2004048343A1 (en) * 2002-11-28 2004-06-10 Schering Aktiengesellschaft Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
DE102005008310A1 (de) * 2005-02-17 2006-08-24 Schering Ag Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle
ATE541848T1 (de) * 2005-05-05 2012-02-15 Ardea Biosciences Inc Diaryl-purin, azapurine und deazapurine als nichtnukleoside reverse-transkriptase-inhibitoren zur behandlung von hiv
AU2007338792B2 (en) * 2006-12-20 2012-05-31 Amgen Inc. Substituted heterocycles and methods of use
EP2142550A1 (en) * 2007-04-02 2010-01-13 Palau Pharma, S.A. Pyrrolopyrimidine derivatives as jak3 inhibitors
MX2009011199A (es) 2007-04-16 2010-03-17 Hutchison Medipharma Entpr Ltd Derivados de pirimidina.
DK2146779T3 (en) * 2007-04-18 2016-11-28 Pfizer Prod Inc Sulfonylamid derivatives to treat abnormal cell growth.
WO2009022171A1 (en) 2007-08-13 2009-02-19 Astrazeneca Ab Pyridinyiioxy pyridines as alk5 inhibitors
EP2179992A1 (de) * 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfonsubstituierte Anlinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
TW201024281A (en) * 2008-11-24 2010-07-01 Boehringer Ingelheim Int New compounds
DE102010014426A1 (de) * 2010-04-01 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
US9145402B2 (en) * 2011-11-29 2015-09-29 Genentech, Inc. Aminopyrimidine derivatives as LRRK2 modulators
NZ629830A (en) * 2014-07-14 2015-12-24 Signal Pharm Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
CN110386901B (zh) 2018-04-23 2022-11-25 上海医药工业研究院 含磺酰苯胺嘧啶结构的化合物及其作为抗肿瘤药物的应用
US12037323B2 (en) 2018-05-03 2024-07-16 Bristol-Myers Squibb Company Uracil derivatives as Mer-AXL inhibitors
US11919904B2 (en) * 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
JP2023515629A (ja) * 2020-02-28 2023-04-13 フォチョン・バイオサイエンシーズ・リミテッド Cdk2/4/6阻害剤としての化合物
WO2022096473A1 (en) * 2020-11-04 2022-05-12 Umicore A positive electrode active material for rechargeable batteries
EP4251613A4 (en) * 2020-11-27 2024-11-20 Allorion Therapeutics Inc. AMINOHETEROARYL KINASE INHIBITORS
US20250009745A1 (en) * 2021-02-05 2025-01-09 Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. Cdk inhibitor

Similar Documents

Publication Publication Date Title
RU2405780C2 (ru) Химические соединения
JP2022533398A5 (cg-RX-API-DMAC7.html)
JP2022505645A5 (cg-RX-API-DMAC7.html)
RU2477723C2 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
JP2022538228A5 (cg-RX-API-DMAC7.html)
JP2022538923A5 (cg-RX-API-DMAC7.html)
JP2022547952A5 (cg-RX-API-DMAC7.html)
JP2016053042A5 (cg-RX-API-DMAC7.html)
RU2011102587A (ru) Дизамещенные фенильные соединения
RU2016120012A (ru) Ингибиторы рецептора фактора роста фибробластов
JP2007524696A5 (cg-RX-API-DMAC7.html)
AR109958A1 (es) Lactamas bicíclicas de piridona y sus métodos de uso
RU2008112691A (ru) Азотсодержащее гетероциклическое соединение и его фармацевтическое применение
JP2020521766A5 (cg-RX-API-DMAC7.html)
CA2679232A1 (en) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
RU2015122126A (ru) Производное пиррол сульфонамида, метод его получения и применение в медицине
JP2020533347A5 (cg-RX-API-DMAC7.html)
JP2014503567A5 (cg-RX-API-DMAC7.html)
JP2007521325A5 (cg-RX-API-DMAC7.html)
JP2014520898A5 (cg-RX-API-DMAC7.html)
RU98117621A (ru) Новые производные пиперазина и пиперидина, способ их получения, фармкомпозиция на их основе, способ лечения, промежуточный продукт
PE20241934A1 (es) Inhibidores de raf quinasa y metodos de uso de los mismos
JP2016529311A5 (cg-RX-API-DMAC7.html)
JP2023535790A5 (cg-RX-API-DMAC7.html)
JP2024539252A5 (cg-RX-API-DMAC7.html)